/PRNewswire/ Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug.
/PRNewswire/ Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug.
Moleculin Commences Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Sarcoma Lung Metastases
- Annamycin was designed to potentially become the first ever non-cardiotoxic anthracycline and has been shown in animal models to accumulate in the lungs at more than 30 times the level of doxorubicin (current standard of care)
- Patient enrollment on track to begin this quarter
- Interim data expected in the second half of 2022
- Annamycin granted Fast Track Status and Orphan Drug Designation from FDA for the treatment of soft tissue sarcoma lung metastases
News provided by
Share this article
HOUSTON, May 25, 2021 /PRNewswire/
Moleculin Reports First Quarter 2021 Financial Results and Provides Programs Update
- Multiple ongoing clinical studies expected to drive key clinical and regulatory milestones throughout next 18 months -
- Significantly strengthened financial position extends cash runway through 2023 -
News provided by
Share this article
HOUSTON, May 12, 2021 /PRNewswire/
Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced its financial results for the quarter ended March 31, 2021. The Company also provided an update on its portfolio of oncology drug candidates for the treatment of highly resistant tumors and viruses.